Precision therapy for intrahepatic cholangiocarcinoma: A case report on adjuvant treatment in a recurrent patient after surgery and literature review

• Published in: Oncology letters 2024-02, Vol.27 (2), Article 56
• Main Authors: Ying, Bao, Tang, Tao, Zhang, Li-Xing, Xiong, Jian-Wei, Zhao, Kai-Feng, Li, Jia-Wei, Wu, Guo
• Format: Article
• Language: English
• Subjects: Abdomen; Antigens; Cancer therapies; Case Report; Case reports; Chemotherapy; Cholangiocarcinoma; Hepatitis B; Hospitals; Immunotherapy; Laboratories; Literature reviews; Liver cancer; Medical records; Medical schools; Metastasis; Monoclonal antibodies; Pancreatic cancer; Patients; Polyclonal antibodies; Surgery; Tumors
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2023.14189

A 37-year-old female patient was diagnosed with intrahepatic cholangiocarcinoma (ICC), with the lesion located in the right lobe of the liver. Despite radical resection, postoperative adjuvant chemotherapy and a combination of adjuvant chemotherapy and immunotherapy, the patient continued to experience multiple instances of intrahepatic tumor metastases. Furthermore, the patient exhibited significant adverse reactions to systemic chemotherapy and had poor treatment tolerance. Guidance from paraffin section fluorescence in situ hybridization gene sequencing was used to select a combination of immunotherapy and targeted therapy treatments with programmed cell death 1 (PD-1)/PD-1 ligand 1 antibody durvalumab and the targeted drug pemigatinib. The patient tolerated the treatment and has continued to survive for 28 months. According to imaging evaluations, the lesions continued to decrease, with some disappearing completely. The tumor marker carbohydrate antigen 19–9 remained normal for >9 weeks during the treatment. This report described the patient's treatment process in detail and briefly reviewed relevant literature on the treatment progress of postoperative patients with ICC.